Table 1. Descriptive statistics of study population.
| Total Population | High Risk ° Patients excluded | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | No NIIT | With NIIT | Total | No NIIT | With NIIT | ||||
| Count | 2714 | 1018 (37.5%) | 1696 (62.5%) | 1948 | 669 (34.3%) | 1279(65.7%) | |||
| Age (Years) | 66.1 | 65.4 | 66.6 | 65.3 | 63.7 | 66.2 | * | ||
| Sex (Female) | 1026 (37.8%) | 374 (36.7%) | 652 (38.4%) | 762 (39.1%) | 243 (36.3%) | 519 (40.6%) | |||
| Deductible Class (Swiss Francs) | |||||||||
| 300 | 1818 (67.0%) | 678 (66.6%) | 1140 (67.2%) | 1303 (66.9%) | 447 (66.8%) | 856 (66.9%) | |||
| 500 | 640 (23.6%) | 244 (24.0%) | 396 (23.3%) | 462 (23.7%) | 159 (23.8%) | 303 (23.7%) | |||
| 1000 | 52 (1.9%) | 24 (2.4%) | 28 (1.7%) | 40 (2.1%) | 16 (2.4%) | 24 (1.9%) | |||
| 1500 | 99 (3.6%) | 32 (3.1%) | 67 (4.0%) | 73 (3.7%) | 22 (3.3%) | 51 (4.0%) | |||
| 2000 | 7 (0.3%) | 3 (0.3%) | 4 (0.2%) | 6 (0.3%) | 3 (0.4%) | 3 (0.2%) | |||
| 2500 | 98 (3.6%) | 37 (3.6%) | 61 (3.6%) | 64 (3.3%) | 22 (3.3%) | 42 (3.3%) | |||
| Supplementary private insurance | 711 (26.2%) | 255 (25.0%) | 456 (26.9%) | 528 (27.1%) | 178 (26.6%) | 350 (27.4%) | |||
| French or Italian part of Switzerland | 880 (32.4%) | 323 (31.7%) | 557 (32.8%) | 625 (32.1%) | 198 (29.6%) | 427 (33.4%) | |||
| Inpatient CA | 1278 (47.1%) | 479 (47.1%) | 799 (47.1%) | 880 (45.2%) | 279 (41.7%) | 601 (47.0%) | * | ||
| ATC_Group 1 | 1219 (44.9%) | 366 (36.0%) | 853 (50.3%) | * | 859 (44.1%) | 220 (32.9%) | 639 (50.0%) | * | |
| ATC_ Group 2 | 947 (34.9%) | 349 (34.3%) | 598 (35.3%) | 643 (33.0%) | 217 (32.4%) | 426 (33.3%) | |||
| ATC_ Group 3 | 1702 (62.7%) | 634 (62.3%) | 1068 (63.0%) | 1185 (60.8%) | 396 (59.2%) | 789 (61.7%) | |||
| ATC_ Group 4 | 403 (14.8%) | 152 (14.9%) | 251 (14.8%) | 280 (14.4%) | 91 (13.6%) | 189 (14.8%) | |||
| Number of chronic conditions (PCG) | 4.5 | 4.6 | 4.4 | * | 4.4 | 4.6 | 4.3 | * | |
Anatomical-Therapeutic-Chemical-Classification (ATC) group 1 = Aspirin, platelet aggregation inhibitors, Group 2 = statins, lipid modifying agents, group 3 = antihypertensives, diuretics, beta blocking agents, calcium channel blockers, agents acting on the renin-angiotensin system, group 4 = antidiabetics. Coronary Angiography (CA). Non-invasive ischemia testing (NIIT). Pharmaceutical cost groups (PCG).
°High risk patients: having received therapeutic cardiac intervention within one month after or 18 Months prior to diagnostic CA.
*p<0.05.